Premium
Effect of zoledronic acid on metastatic hormone‐refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone
Author(s) -
Kikuno Nobuyuki,
Urakami Shinji,
Nakamura Shigeru,
Shiina Hiroaki,
Igawa Mikio
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01566.x
Subject(s) - estramustine , medicine , zoledronic acid , taxane , carboplatin , prostate cancer , oncology , dexamethasone , bone metastasis , refractory (planetary science) , prostate , cancer , chemotherapy , breast cancer , cisplatin , biology , prostate disease , astrobiology
This case report demonstrates the effect of zoledronic acid (ZA) on a patient with bone metastatic hormone‐refractory prostate cancer (HRPC) resistant to taxane, estramustine phosphate, carboplatin, and dexamethasone. The pathogenesis, diagnosis, and management of bone metastasis on HRPC are also reviewed.